Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly traded biopharmaceutical company focused on the discovery, development, and commercialization of a cure for chronic hepatitis B virus (HBV) infection. The company is headquartered in Warminster, Pennsylvania, and it operates in the biotechnology and pharmaceutical industries.
History[edit | edit source]
Arbutus Biopharma was originally founded as Tekmira Pharmaceuticals Corporation in 2005. In 2015, the company rebranded itself as Arbutus Biopharma Corporation following the acquisition of OnCore Biopharma. The merger aimed to combine Tekmira's expertise in lipid nanoparticle (LNP) technology with OnCore's focus on HBV therapies.
Research and Development[edit | edit source]
Arbutus Biopharma's research and development efforts are primarily centered on finding a cure for chronic hepatitis B. The company's approach includes the development of RNA interference (RNAi) therapeutics, small molecule antivirals, and immune modulators.
RNA Interference (RNAi) Therapeutics[edit | edit source]
RNAi therapeutics are designed to silence specific genes associated with HBV replication. Arbutus has developed several RNAi candidates, including AB-729, which is currently in clinical trials.
Small Molecule Antivirals[edit | edit source]
Arbutus is also working on small molecule antivirals that target various stages of the HBV life cycle. These compounds aim to inhibit the replication of the virus and reduce the viral load in patients.
Immune Modulators[edit | edit source]
The company is exploring immune modulators to enhance the body's immune response against HBV. These therapies aim to boost the immune system's ability to recognize and eliminate HBV-infected cells.
Pipeline[edit | edit source]
Arbutus Biopharma has a robust pipeline of investigational drugs targeting HBV. Some of the key candidates include:
- AB-729: An RNAi therapeutic in clinical trials.
- AB-836: A capsid inhibitor designed to disrupt the HBV life cycle.
- AB-101: An immune modulator aimed at enhancing the immune response.
Collaborations and Partnerships[edit | edit source]
Arbutus Biopharma has established several collaborations and partnerships to advance its research and development efforts. Notable partners include Alnylam Pharmaceuticals, Genevant Sciences, and the Bill & Melinda Gates Foundation.
Financial Information[edit | edit source]
Arbutus Biopharma is listed on the NASDAQ stock exchange under the ticker symbol "ABUS." The company has secured funding through various rounds of financing, including public offerings and private investments.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
| <img src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Searchtool.svg/40px-Searchtool.svg.png" alt="Stub icon" width="40" height="40" /> | This biopharmaceutical related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
